Form 8-K - Current report:
SEC Accession No. 0001213900-25-021738
Filing Date
2025-03-07
Accepted
2025-03-07 16:15:08
Documents
13
Period of Report
2025-03-05
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0233491-8k_adial.htm   iXBRL 8-K 26166
  Complete submission text file 0001213900-25-021738.txt   199218

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE adil-20250305.xsd EX-101.SCH 3006
3 XBRL LABEL FILE adil-20250305_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE adil-20250305_pre.xml EX-101.PRE 22353
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0233491-8k_adial_htm.xml XML 3657
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 25720241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)